The board of Eurocine Vaccines has decided to develop a vaccine candidate against chlamydia using mRNA, the next generation vaccine technology. The technology enables development synergies with other vaccine candidates in portfolio, gaining competitive edge with less investments. At the same time, the company decides to pause the resource-intensive development of the protein-based chlamydia candidate until further notice.

Being at the forefront in vaccine development, Eurocine Vaccines has decided to develop a vaccine candidate against chlamydia using the modern mRNA technology. The goal is to conduct preclinical studies and early mRNA development in the near term, to begin process development and other preparations in the fourth quarter of 2023, ahead of toxicological and then clinical trials. The resource-intensive development of the protein-based chlamydia vaccine candidate will be paused until further notice.

The mRNA-based vaccine candidate against chlamydia encodes for the same protein that has earlier been successfully documented and is covered by the same patent and exclusive global licensing agreement. This strengthens the conditions for success with the mRNA candidate.